ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adrenoleukodystrophy Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-28Y8829
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Adrenoleukodystrophy Drugs Market Outlook 2022
BUY CHAPTERS

Global Adrenoleukodystrophy Drugs Market Research Report 2025

Code: QYRE-Auto-28Y8829
Report
August 2025
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
Bluebird bio
Rocket Pharmaceuticals
Lysogene
Sangamo Therapeutics

Adrenoleukodystrophy Drugs Market Size

The global market for Adrenoleukodystrophy Drugs was valued at US$ 253 million in the year 2024 and is projected to reach a revised size of US$ 591 million by 2031, growing at a CAGR of 10.9% during the forecast period.

Adrenoleukodystrophy Drugs Market

Adrenoleukodystrophy Drugs Market

Adrenoleukodystrophy (ALD) drugs are therapeutic solutions designed to prevent, slow, or reverse the neurodegenerative and endocrine manifestations caused by mutations in the ABCD1 gene, which lead to accumulation of very-long-chain fatty acids (VLCFAs) in the central nervous system and adrenal glands. The therapeutic landscape includes metabolic interventions (aimed at modulating fatty-acid metabolism and symptomatic support), hematopoietic stem cell transplant (HSCT)-related approaches that can arrest cerebral disease progression when performed early, and the more recent single-administration gene-replacement therapies that correct the underlying genetic defect in autologous cells. Clinical strategies differ markedly by phenotype — childhood cerebral ALD (CALD), adrenomyeloneuropathy (AMN), or adrenal insufficiency — and thus vary in mechanism of action, delivery modality, and regulatory pathway. Gene therapy introduces a potentially transformative one-time option for boys with early, active CALD who lack matched donors, while also imposing long-term safety monitoring and complex commercialization and reimbursement considerations. Overall, ALD drugs now span from conventional supportive regimens to advanced cell and gene therapeutics, reshaping clinical practice, payer evaluation, and R&D priorities in this ultra-rare disease area.
The ALD therapeutic space is experiencing an inflection point driven by the maturation of precision medicine and regulatory prioritization of rare-disease innovation. Regulatory acceleration and conditional approvals for one-time gene-replacement therapies have created a commercially viable pathway for treating boys with early, active CALD who lack matched donors—transforming clinical algorithms and motivating payers and providers to negotiate long-term outcome-based arrangements. Public health initiatives and expanded newborn or targeted screening programs are improving early detection rates, which in turn expand the addressable population for curative and high-value interventions. Companies that integrate R&D, manufacturing and Centers of Excellence into a coordinated delivery model can secure differentiated market access and durable clinical partnerships.
Innovation risk and commercialization complexity are prominent restraints. While gene therapies demonstrate compelling efficacy, long-term safety concerns—particularly vector integration–related hematologic malignancies—require extended monitoring and complicate regulatory labeling and payer coverage, thereby affecting adoption speed. Cross-border launches face heterogeneous reimbursement frameworks for ultra-rare, high-cost therapies; manufacturing and logistics for autologous cell-based products demand significant capital and operational capabilities. The patient population is inherently small and clinically heterogeneous, constraining rapid scale-up and return on investment. Company filings and regulatory communiqués highlight that sponsors must manage clinical, regulatory and health-economic pressures in parallel.
Downstream demand is shifting toward an integrated “screen—treat—manage” ecosystem. Rising newborn and targeted screening rates will increase demand for early definitive interventions (HSCT or gene therapy), while families and clinicians will require robust long-term safety, quality-of-life, and functional-outcome data—driving growth in follow-up services and supportive care. Payers are increasingly receptive to innovative reimbursement constructs tied to long-term outcomes, prompting sponsors to design post-marketing evidence-generation strategies and scalable follow-up infrastructures. Consequently, procurement will evolve from single-product purchases toward bundled offerings that combine diagnostics, therapeutic delivery, and longitudinal outcomes management.
This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs.
The Adrenoleukodystrophy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adrenoleukodystrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adrenoleukodystrophy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Adrenoleukodystrophy Drugs Market Report

Report Metric Details
Report Name Adrenoleukodystrophy Drugs Market
Accounted market size in year US$ 253 million
Forecasted market size in 2031 US$ 591 million
CAGR 10.9%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Hormone Replacement
  • Transplant
  • Others
Segment by Application
  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bluebird Bio, NeuroVia, Orpheris, Minoryx, MedDay Pharmaceuticals, Rocket Pharmaceuticals, Lysogene, Sangamo Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Adrenoleukodystrophy Drugs Market growing?

Ans: The Adrenoleukodystrophy Drugs Market witnessing a CAGR of 10.9% during the forecast period 2025-2031.

What is the Adrenoleukodystrophy Drugs Market size in 2031?

Ans: The Adrenoleukodystrophy Drugs Market size in 2031 will be US$ 591 million.

Who are the main players in the Adrenoleukodystrophy Drugs Market report?

Ans: The main players in the Adrenoleukodystrophy Drugs Market are Bluebird Bio, NeuroVia, Orpheris, Minoryx, MedDay Pharmaceuticals, Rocket Pharmaceuticals, Lysogene, Sangamo Therapeutics

What are the Application segmentation covered in the Adrenoleukodystrophy Drugs Market report?

Ans: The Applications covered in the Adrenoleukodystrophy Drugs Market report are Childhood Cerebral ALD, Adrenomyeloneuropathy (AMN), Addison-only, Others

What are the Type segmentation covered in the Adrenoleukodystrophy Drugs Market report?

Ans: The Types covered in the Adrenoleukodystrophy Drugs Market report are Hormone Replacement, Transplant, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormone Replacement
1.2.3 Transplant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Childhood Cerebral ALD
1.3.3 Adrenomyeloneuropathy (AMN)
1.3.4 Addison-only
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adrenoleukodystrophy Drugs Market Perspective (2020-2031)
2.2 Global Adrenoleukodystrophy Drugs Growth Trends by Region
2.2.1 Global Adrenoleukodystrophy Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Adrenoleukodystrophy Drugs Historic Market Size by Region (2020-2025)
2.2.3 Adrenoleukodystrophy Drugs Forecasted Market Size by Region (2026-2031)
2.3 Adrenoleukodystrophy Drugs Market Dynamics
2.3.1 Adrenoleukodystrophy Drugs Industry Trends
2.3.2 Adrenoleukodystrophy Drugs Market Drivers
2.3.3 Adrenoleukodystrophy Drugs Market Challenges
2.3.4 Adrenoleukodystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoleukodystrophy Drugs Players by Revenue
3.1.1 Global Top Adrenoleukodystrophy Drugs Players by Revenue (2020-2025)
3.1.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Adrenoleukodystrophy Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Adrenoleukodystrophy Drugs Revenue
3.4 Global Adrenoleukodystrophy Drugs Market Concentration Ratio
3.4.1 Global Adrenoleukodystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Drugs Revenue in 2024
3.5 Global Key Players of Adrenoleukodystrophy Drugs Head office and Area Served
3.6 Global Key Players of Adrenoleukodystrophy Drugs, Product and Application
3.7 Global Key Players of Adrenoleukodystrophy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoleukodystrophy Drugs Breakdown Data by Type
4.1 Global Adrenoleukodystrophy Drugs Historic Market Size by Type (2020-2025)
4.2 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Type (2026-2031)
5 Adrenoleukodystrophy Drugs Breakdown Data by Application
5.1 Global Adrenoleukodystrophy Drugs Historic Market Size by Application (2020-2025)
5.2 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Adrenoleukodystrophy Drugs Market Size (2020-2031)
6.2 North America Adrenoleukodystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Adrenoleukodystrophy Drugs Market Size by Country (2020-2025)
6.4 North America Adrenoleukodystrophy Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Drugs Market Size (2020-2031)
7.2 Europe Adrenoleukodystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Adrenoleukodystrophy Drugs Market Size by Country (2020-2025)
7.4 Europe Adrenoleukodystrophy Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Adrenoleukodystrophy Drugs Market Size (2020-2031)
8.2 Asia-Pacific Adrenoleukodystrophy Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Adrenoleukodystrophy Drugs Market Size (2020-2031)
9.2 Latin America Adrenoleukodystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Adrenoleukodystrophy Drugs Market Size by Country (2020-2025)
9.4 Latin America Adrenoleukodystrophy Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoleukodystrophy Drugs Market Size (2020-2031)
10.2 Middle East & Africa Adrenoleukodystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Adrenoleukodystrophy Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Adrenoleukodystrophy Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bluebird Bio
11.1.1 Bluebird Bio Company Details
11.1.2 Bluebird Bio Business Overview
11.1.3 Bluebird Bio Adrenoleukodystrophy Drugs Introduction
11.1.4 Bluebird Bio Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.1.5 Bluebird Bio Recent Development
11.2 NeuroVia
11.2.1 NeuroVia Company Details
11.2.2 NeuroVia Business Overview
11.2.3 NeuroVia Adrenoleukodystrophy Drugs Introduction
11.2.4 NeuroVia Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.2.5 NeuroVia Recent Development
11.3 Orpheris
11.3.1 Orpheris Company Details
11.3.2 Orpheris Business Overview
11.3.3 Orpheris Adrenoleukodystrophy Drugs Introduction
11.3.4 Orpheris Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.3.5 Orpheris Recent Development
11.4 Minoryx
11.4.1 Minoryx Company Details
11.4.2 Minoryx Business Overview
11.4.3 Minoryx Adrenoleukodystrophy Drugs Introduction
11.4.4 Minoryx Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.4.5 Minoryx Recent Development
11.5 MedDay Pharmaceuticals
11.5.1 MedDay Pharmaceuticals Company Details
11.5.2 MedDay Pharmaceuticals Business Overview
11.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Introduction
11.5.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.5.5 MedDay Pharmaceuticals Recent Development
11.6 Rocket Pharmaceuticals
11.6.1 Rocket Pharmaceuticals Company Details
11.6.2 Rocket Pharmaceuticals Business Overview
11.6.3 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Introduction
11.6.4 Rocket Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.6.5 Rocket Pharmaceuticals Recent Development
11.7 Lysogene
11.7.1 Lysogene Company Details
11.7.2 Lysogene Business Overview
11.7.3 Lysogene Adrenoleukodystrophy Drugs Introduction
11.7.4 Lysogene Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.7.5 Lysogene Recent Development
11.8 Sangamo Therapeutics
11.8.1 Sangamo Therapeutics Company Details
11.8.2 Sangamo Therapeutics Business Overview
11.8.3 Sangamo Therapeutics Adrenoleukodystrophy Drugs Introduction
11.8.4 Sangamo Therapeutics Revenue in Adrenoleukodystrophy Drugs Business (2020-2025)
11.8.5 Sangamo Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
Bluebird bio
Rocket Pharmaceuticals
Lysogene
Sangamo Therapeutics
List of Tables
 Table 1. Global Adrenoleukodystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Hormone Replacement
 Table 3. Key Players of Transplant
 Table 4. Key Players of Others
 Table 5. Global Adrenoleukodystrophy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Adrenoleukodystrophy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Adrenoleukodystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Adrenoleukodystrophy Drugs Market Share by Region (2020-2025)
 Table 9. Global Adrenoleukodystrophy Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Adrenoleukodystrophy Drugs Market Share by Region (2026-2031)
 Table 11. Adrenoleukodystrophy Drugs Market Trends
 Table 12. Adrenoleukodystrophy Drugs Market Drivers
 Table 13. Adrenoleukodystrophy Drugs Market Challenges
 Table 14. Adrenoleukodystrophy Drugs Market Restraints
 Table 15. Global Adrenoleukodystrophy Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Adrenoleukodystrophy Drugs Market Share by Players (2020-2025)
 Table 17. Global Top Adrenoleukodystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)
 Table 18. Ranking of Global Top Adrenoleukodystrophy Drugs Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Adrenoleukodystrophy Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Adrenoleukodystrophy Drugs, Headquarters and Area Served
 Table 21. Global Key Players of Adrenoleukodystrophy Drugs, Product and Application
 Table 22. Global Key Players of Adrenoleukodystrophy Drugs, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Adrenoleukodystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2020-2025)
 Table 26. Global Adrenoleukodystrophy Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2026-2031)
 Table 28. Global Adrenoleukodystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2020-2025)
 Table 30. Global Adrenoleukodystrophy Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2026-2031)
 Table 32. North America Adrenoleukodystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Adrenoleukodystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Adrenoleukodystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Adrenoleukodystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Adrenoleukodystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Adrenoleukodystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Adrenoleukodystrophy Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Adrenoleukodystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Adrenoleukodystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Adrenoleukodystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Adrenoleukodystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Adrenoleukodystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Adrenoleukodystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Bluebird Bio Company Details
 Table 48. Bluebird Bio Business Overview
 Table 49. Bluebird Bio Adrenoleukodystrophy Drugs Product
 Table 50. Bluebird Bio Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 51. Bluebird Bio Recent Development
 Table 52. NeuroVia Company Details
 Table 53. NeuroVia Business Overview
 Table 54. NeuroVia Adrenoleukodystrophy Drugs Product
 Table 55. NeuroVia Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 56. NeuroVia Recent Development
 Table 57. Orpheris Company Details
 Table 58. Orpheris Business Overview
 Table 59. Orpheris Adrenoleukodystrophy Drugs Product
 Table 60. Orpheris Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 61. Orpheris Recent Development
 Table 62. Minoryx Company Details
 Table 63. Minoryx Business Overview
 Table 64. Minoryx Adrenoleukodystrophy Drugs Product
 Table 65. Minoryx Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 66. Minoryx Recent Development
 Table 67. MedDay Pharmaceuticals Company Details
 Table 68. MedDay Pharmaceuticals Business Overview
 Table 69. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product
 Table 70. MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 71. MedDay Pharmaceuticals Recent Development
 Table 72. Rocket Pharmaceuticals Company Details
 Table 73. Rocket Pharmaceuticals Business Overview
 Table 74. Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Product
 Table 75. Rocket Pharmaceuticals Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 76. Rocket Pharmaceuticals Recent Development
 Table 77. Lysogene Company Details
 Table 78. Lysogene Business Overview
 Table 79. Lysogene Adrenoleukodystrophy Drugs Product
 Table 80. Lysogene Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 81. Lysogene Recent Development
 Table 82. Sangamo Therapeutics Company Details
 Table 83. Sangamo Therapeutics Business Overview
 Table 84. Sangamo Therapeutics Adrenoleukodystrophy Drugs Product
 Table 85. Sangamo Therapeutics Revenue in Adrenoleukodystrophy Drugs Business (2020-2025) & (US$ Million)
 Table 86. Sangamo Therapeutics Recent Development
 Table 87. Research Programs/Design for This Report
 Table 88. Key Data Information from Secondary Sources
 Table 89. Key Data Information from Primary Sources
 Table 90. Authors List of This Report


List of Figures
 Figure 1. Adrenoleukodystrophy Drugs Picture
 Figure 2. Global Adrenoleukodystrophy Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Adrenoleukodystrophy Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Hormone Replacement Features
 Figure 5. Transplant Features
 Figure 6. Others Features
 Figure 7. Global Adrenoleukodystrophy Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Adrenoleukodystrophy Drugs Market Share by Application: 2024 VS 2031
 Figure 9. Childhood Cerebral ALD Case Studies
 Figure 10. Adrenomyeloneuropathy (AMN) Case Studies
 Figure 11. Addison-only Case Studies
 Figure 12. Others Case Studies
 Figure 13. Adrenoleukodystrophy Drugs Report Years Considered
 Figure 14. Global Adrenoleukodystrophy Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Adrenoleukodystrophy Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Adrenoleukodystrophy Drugs Market Share by Region: 2024 VS 2031
 Figure 17. Global Adrenoleukodystrophy Drugs Market Share by Players in 2024
 Figure 18. Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 19. The Top 10 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2024
 Figure 20. North America Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Adrenoleukodystrophy Drugs Market Share by Country (2020-2031)
 Figure 22. United States Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Adrenoleukodystrophy Drugs Market Share by Country (2020-2031)
 Figure 26. Germany Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Ireland Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Adrenoleukodystrophy Drugs Market Share by Region (2020-2031)
 Figure 34. China Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia & New Zealand Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Adrenoleukodystrophy Drugs Market Share by Country (2020-2031)
 Figure 42. Mexico Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Adrenoleukodystrophy Drugs Market Share by Country (2020-2031)
 Figure 46. Israel Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Adrenoleukodystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Bluebird Bio Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 50. NeuroVia Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 51. Orpheris Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 52. Minoryx Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 53. MedDay Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 54. Rocket Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 55. Lysogene Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 56. Sangamo Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Drugs Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Adrenoleukodystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metachromatic Leukodystrophy Treatment Market Research Report 2025
Inherited Metabolic Disorder Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Krabbe Disease Treatment Market Research Report 2024
Global Sphingolipidoses Treatment Market Research Report 2025
Global Lysosomal Storage Disease Treatment Drugs Market Research Report 2024
Age relatedMacularDegeneration ARMD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sickle cell Anemia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Rare Neurodegenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lysosomal Storage Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Farber s Disease Market Research Report 2024
Adenosine Deaminase Deficiency Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Fabry Disease Treatment Market Insights Forecast to 2030
Adenosine Deaminase Deficiency Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lewy Body Dementia Treatment Market Research Report 2024
Global Propionic Acidemia Treat Market Research Report 2025
Global CDKL5 Deficiency Disorder CDD Market Research Report 2024
Global Gaucher Disease GD Drugs Market Insights Forecast to 2030
Global Urea Cycle Disorder UCD Drugs Market Research Report 2024
Global Addison s Disease Treatment Market Insights Forecast to 2030

RELATED REPORTS

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24R5886
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Lysosomal Storage Diseases Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34Q5936
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Acute Intermittent Porphyria Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6U7336
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Phenylketonuria Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12R6229
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions